Cannabis Company Khiron Life Sciences Making Inroads In Latin America

Cannabis Company Khiron Life Sciences Making Inroads In Latin America

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, August 14, 2018

The cannabis industry has been growing at break-neck speed over the past few years, with countless companies jumping in the pool attempting to capitalize off this prolific growth. As a result, the industry is fragmented, comprised of many small players fighting tooth and nail for market share.

Among them is Khiron Life Sciences (TSX-Venture:KHRN), aiming to launch operations in Latin America. The company provides a myriad of products and services based on marijuana, ranging from medical products to “cosmeceuticals”. However, their biggest path to growth seems to be in providing medical marijuana-related products and services to treat patients with unmet medical needs across the region – a number which is pinned to be in the tens of millions.

Just several days ago, Khiron acquired the Latin American Institute of Neurology and Nervous Systems (a.k.a., “ILANS”), a Colombian health service provider network, for $7 million in cash (70%, $4.9 million) and stock (30%, $2.1 million). The name of the game in this deal was patient acquisition, which provides Khiron with immediate revenue and EBITDA recognition. ILANS generated $10.5 million CAD in 2017, and $1.8 million in EBITDA; this puts FY17 EBITDA margin at ~17% up over 600 basis points y/y. Revenue has grown at a CAGR of over 28% since 2012.

The deal provides Khiron with roughly 100,000 patient accounts, and contingencies in place for ILANS to receive more cash ($5 mln) should they meet patient acquisition requirements set in the deal terms. As mentioned before, 30% of the deal was financed by stock, although concerns here are dampened given the 2-year lock up period. Investors need not be worried about immediate selling pressure stemming from the deal – although investors should certainly keep tabs on the lock up expiration date.

As far as immediate cash impact is concerned, the company will be providing 20% of the cash upon closing ($980,000), and the remaining 80% ($3.92 million) over the course of two years. Although exact terms were not disclosed, this would put monthly payments at only $163,000. The structure of the deal appears to be beneficial for Khiron, allowing them to conduct operations with their newly acquired medical clinics with minimal cash impact in the short-term. This gives them the elbow room they need to grow without constraints.

When looking at the industry as a whole in the LatAm region, Khiron only holds a ~2% market share – while some may see this is as a con, the fragmented nature of the business actually provides Khiron with growth potential in consolidating the industry through M&A. Khiron’s healthy balance sheet is another key plus in the thesis. The company is not levered, with a 1x debt/equity ratio, and is solvent with a quick ratio of 1x as well. Working capital is $673K CAD, with a current ratio of ~1.6x. Their investment-grade credit rating further opens the door to debt-financed M&A, and of course, increased market share and revenues.

Their main medical cannabis products are expected to launch in 2019 and 2020, with management expecting annual revenue per patient to be $550 CAD/year. This could translate into potential revenues of $55 million

CAD in 2020 for only the 100,000 patient accounts provided by ILANS. Even if all 100,000 accounts are not successfully converted, the company’s access to capital and M&A abilities could allow it to acquire many more accounts – and turn up even higher-than-expected top-line results, with relatively comfortable debt servicing costs.

In the near term, Khiron Wellness, the company’s cosmeceutical products are planned for 4Q18, with eight of their CBD-based products already approved by INVIMA (think: Colombian FDA). Gross margins on these products are in the low-70% range, and management predicts revenues could reach $29 mln CAD by 2020. When combined, this would put revenue at $84 million in 2020 – with gross margins in the 70-80% range, operating expenses would be what make or break the company’s profitability.

The upside is certainly lucrative, with the primary risk being Khiron failing to translate their M&A efforts into growth, among other things. When connecting the dots, you have a company which is well positioned to take on the rapid growth in the marijuana industry – through consolidation, and organic means as well. The potential reward may outweigh the risks at the moment.


Copyright © 2018 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Miner Scores with Acquisition of Promising Silver District in Mexico
Mixed Signals: Durable Goods Orders Up, But Not All Sectors Are Soaring
Biotech Steals The Show Following Pre-Clinical Data Announcement
Most Popular
5
FREE Newsletter


Back to Top